Silk Road Medical, Inc (NASDAQ:SILK – Get Rating) shares reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $54.06 and last traded at $53.52, with a volume of 11210 shares traded. The stock had previously closed at $50.90.
Analyst Upgrades and Downgrades
SILK has been the subject of several recent analyst reports. Citigroup lifted their price target on Silk Road Medical to $38.00 in a research report on Tuesday, November 15th. Bank of America began coverage on Silk Road Medical in a report on Tuesday. They issued a “buy” rating and a $60.00 price objective for the company.
Silk Road Medical Stock Up 2.3 %
The stock has a 50 day simple moving average of $45.18 and a 200-day simple moving average of $41.05. The company has a debt-to-equity ratio of 1.30, a quick ratio of 5.29 and a current ratio of 6.14.
Insider Buying and Selling at Silk Road Medical
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in the stock. M&T Bank Corp lifted its holdings in Silk Road Medical by 4.0% in the 3rd quarter. M&T Bank Corp now owns 74,679 shares of the company’s stock worth $3,361,000 after purchasing an additional 2,890 shares in the last quarter. Kayne Anderson Rudnick Investment Management LLC lifted its holdings in Silk Road Medical by 4.3% in the 3rd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,404,788 shares of the company’s stock worth $63,216,000 after purchasing an additional 57,544 shares in the last quarter. Balyasny Asset Management LLC purchased a new position in Silk Road Medical in the 3rd quarter worth approximately $7,096,000. BNP Paribas Arbitrage SNC lifted its holdings in Silk Road Medical by 170.1% in the 3rd quarter. BNP Paribas Arbitrage SNC now owns 20,871 shares of the company’s stock worth $939,000 after purchasing an additional 13,144 shares in the last quarter. Finally, Thrivent Financial for Lutherans lifted its holdings in Silk Road Medical by 5.6% in the 3rd quarter. Thrivent Financial for Lutherans now owns 403,177 shares of the company’s stock worth $18,143,000 after purchasing an additional 21,521 shares in the last quarter.
Silk Road Medical Company Profile
Silk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization. Its products include ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices.
- Get a free copy of the StockNews.com research report on Silk Road Medical (SILK)
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Institutional Support for Analog Devices Remains High
- Is the 60/40 Portfolio Mix Still in Vogue?
- Microsoft Shares: Is it Time to Back Up the Truck?
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for Silk Road Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silk Road Medical and related companies with MarketBeat.com's FREE daily email newsletter.